SignatureFD wants to stay independent yet be competitive with investor-backed firms writing big checks, its CEO says.

The next CEO of Raymond James talks about how private equity ownership has made for some difficult marriages in wealth ...

Fintel reports that on February 11, 2025, Raymond James downgraded their outlook for Third Harmonic Bio (NasdaqGM:THRD) from ...

Stock analysts at Raymond James lowered their FY2025 EPS estimates for shares of Canaccord Genuity Group in a report issued ...

From security to development, the wealth management firm uses the Dynatrace platform to give senior executives information on ...

James increased the price target for INmune Bio Inc. (NASDAQ: NASDAQ:INMB) shares to $23 from the previous $18, while maintaining an Outperform rating. According to InvestingPro data, the stock ...

Equities researchers at Raymond James issued their Q3 2025 earnings per share (EPS) estimates for shares of Uranium Royalty in a report issued on Wednesday, February 5th. Raymond James analyst B.

Uncover why the promises of the second Trump administration have contractors concerned about spending and acquisition funding ...

In a report released on February 7, Kevin Heal from Argus Research maintained a Buy rating on Raymond James Financial (RJF – Research Report).

Ares Capital's recent earnings miss doesn't overshadow its strong growth and stable dividend, making it a long-term income investment. See more on ARCC here.